Skip to main content

Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.

Citation
Group, D. P. P. R. “Long-Term Effects Of Metformin On Diabetes Prevention: Identification Of Subgroups That Benefited Most In The Diabetes Prevention Program And Diabetes Prevention Program Outcomes Study.”. Diabetes Care, pp. 601-608.
Center University of Washington
Author Diabetes Prevention Program Research Group
Abstract

OBJECTIVE: We examined the effects of metformin on diabetes prevention and the subgroups that benefited most over 15 years in the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS).

RESEARCH DESIGN AND METHODS: During the DPP (1996-2001), adults at high risk of developing diabetes were randomly assigned to masked placebo ( = 1,082) or metformin 850 mg twice daily ( = 1,073). Participants originally assigned to metformin continued to receive metformin, unmasked, in the DPPOS (2002-present). Ascertainment of diabetes development was based on fasting or 2-h glucose levels after an oral glucose tolerance test or on HbA. Reduction in diabetes incidence with metformin was compared with placebo in subgroups by hazard ratio (HR) and rate differences (RDs).

RESULTS: During 15 years of postrandomization follow-up, metformin reduced the incidence (by HR) of diabetes compared to placebo by 17% or 36% based on glucose or HbA levels, respectively. Metformin's effect on the development of glucose-defined diabetes was greater for women with a history of prior gestational diabetes mellitus (GDM) (HR 0.59, RD -4.57 cases/100 person-years) compared with parous women without GDM (HR 0.94, RD -0.38 cases/100 person-years [interaction = 0.03 for HR, = 0.01 for RD]). Metformin also had greater effects, by HR and RD, at higher baseline fasting glucose levels. With diabetes development based on HbA, metformin was more effective in subjects with higher baseline HbA by RD, with metformin RD -1.03 cases/100 person-years with baseline HbA <6.0% (42 mmol/mol) and -3.88 cases/100 person-years with 6.0-6.4% ( = 0.0001).

CONCLUSIONS: Metformin reduces the development of diabetes over 15 years. The subsets that benefitted the most include subjects with higher baseline fasting glucose or HbA and women with a history of GDM.

Year of Publication
2019
Journal
Diabetes care
Volume
42
Issue
4
Number of Pages
601-608
Date Published
12/2019
ISSN Number
1935-5548
DOI
10.2337/dc18-1970
Alternate Journal
Diabetes Care
PMID
30877090
PMCID
PMC6429636
Download citation